Drugmakers Aim to Enter Obesity Drug Market Dominated by Novo Nordisk, Eli Lilly

Pharmaceutical companies are reportedly looking to enter the growing obesity drug market. This initiative comes as major drugmakers aim to secure a position within a sector known for its significant potential.

The current landscape of the obesity drug market is predominantly controlled by two key players: Novo Nordisk and Eli Lilly. These companies have established a dominant presence in the industry.

According to CNBC Business, various drugmakers are strategizing to penetrate this market, signaling increased competition in the pharmaceutical sector.